Cargando…
Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation
In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfold...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047295/ https://www.ncbi.nlm.nih.gov/pubmed/36980299 http://dx.doi.org/10.3390/cells12060960 |
_version_ | 1785013885095378944 |
---|---|
author | Naus, Evelyne Derweduwe, Marleen Lampi, Youlia Claeys, Annelies Pauwels, Jarne Langenberg, Tobias Claes, Filip Xu, Jie Haemels, Veerle Atak, Zeynep Kalender van der Kant, Rob Van Durme, Joost De Baets, Greet Ligon, Keith L. Fiers, Mark Gevaert, Kris Aerts, Stein Rousseau, Frederic Schymkowitz, Joost De Smet, Frederik |
author_facet | Naus, Evelyne Derweduwe, Marleen Lampi, Youlia Claeys, Annelies Pauwels, Jarne Langenberg, Tobias Claes, Filip Xu, Jie Haemels, Veerle Atak, Zeynep Kalender van der Kant, Rob Van Durme, Joost De Baets, Greet Ligon, Keith L. Fiers, Mark Gevaert, Kris Aerts, Stein Rousseau, Frederic Schymkowitz, Joost De Smet, Frederik |
author_sort | Naus, Evelyne |
collection | PubMed |
description | In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting. |
format | Online Article Text |
id | pubmed-10047295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100472952023-03-29 Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation Naus, Evelyne Derweduwe, Marleen Lampi, Youlia Claeys, Annelies Pauwels, Jarne Langenberg, Tobias Claes, Filip Xu, Jie Haemels, Veerle Atak, Zeynep Kalender van der Kant, Rob Van Durme, Joost De Baets, Greet Ligon, Keith L. Fiers, Mark Gevaert, Kris Aerts, Stein Rousseau, Frederic Schymkowitz, Joost De Smet, Frederik Cells Article In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting. MDPI 2023-03-21 /pmc/articles/PMC10047295/ /pubmed/36980299 http://dx.doi.org/10.3390/cells12060960 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naus, Evelyne Derweduwe, Marleen Lampi, Youlia Claeys, Annelies Pauwels, Jarne Langenberg, Tobias Claes, Filip Xu, Jie Haemels, Veerle Atak, Zeynep Kalender van der Kant, Rob Van Durme, Joost De Baets, Greet Ligon, Keith L. Fiers, Mark Gevaert, Kris Aerts, Stein Rousseau, Frederic Schymkowitz, Joost De Smet, Frederik Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title | Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title_full | Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title_fullStr | Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title_full_unstemmed | Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title_short | Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation |
title_sort | reduced levels of misfolded and aggregated mutant p53 by proteostatic activation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047295/ https://www.ncbi.nlm.nih.gov/pubmed/36980299 http://dx.doi.org/10.3390/cells12060960 |
work_keys_str_mv | AT nausevelyne reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT derweduwemarleen reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT lampiyoulia reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT claeysannelies reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT pauwelsjarne reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT langenbergtobias reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT claesfilip reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT xujie reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT haemelsveerle reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT atakzeynepkalender reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT vanderkantrob reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT vandurmejoost reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT debaetsgreet reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT ligonkeithl reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT fiersmark reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT gevaertkris reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT aertsstein reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT rousseaufrederic reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT schymkowitzjoost reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation AT desmetfrederik reducedlevelsofmisfoldedandaggregatedmutantp53byproteostaticactivation |